



Study Schema



Supplemental
Figure 2(a) Progression-free survival in the second registration (combination therapy) by primary treatment duration




12 months and longer

No. at risk	39	31	23	17	14	7	5	3	2	1	0
Event	0	4	6	4	3	4	0	0	0	0	1

Less than 12 months


No. at risk	33	28	18	14	9	5	2	1	1	0	0
Event	0	5	9	4	5	2	3	1	0	0	0

Supplemental
Figure 2(b) Progression-free survival by primary and secondary fulvestrant therapy



FUL primary therapy											
No. at risk	20	16	10	7	5	3	2	2	2	1	0
Event	0	2	6	2	2	1	0	0	0	0	1
FUL secondary therapy											
No. at risk	52	43	31	24	18	9	5	2	1	0	0
Event	0	7	9	6	6	5	3	1	0	0	0

Supplemental
Figure 2(c) Progression-free survival in second registration (combination therapy) by visceral metastasis




Without metastasis

No. at risk	34	29	21	17	15	10	6	4	3	1	0
Event	0	4	7	3	2	3	3	0	0	0	1

With metastasis

No. at risk	38	30	20	14	8	2	1	0	0	0	0
Event	0	5	8	5	6	3	0	1	0	0	0

Supplemental
Figure 2(d) Comparison of progression-free survival in second-registration (combination therapy) between *de novo* stage IV and metastatic cancer



De novo stage IV

No. at risk	18	14	10	7	5	3	2	1	1	1	0
Event	0	3	3	3	2	1	1	0	0	0	1

Metastatic

No. at risk	54	45	31	24	18	9	5	3	2	0	0
Event	0	6	12	5	6	5	2	1	0	0	0